Primary biliary cirrhosis in adults.

Area of Science:

• Hepatology
• Autoimmune Diseases
• Gastroenterology

Background:

• Primary biliary cirrhosis (PBC) is a chronic, autoimmune cholestatic liver disease characterized by progressive destruction of intrahepatic bile ducts.
• It leads to impaired bile secretion, toxic bile acid accumulation, liver fibrosis, and cirrhosis, with increasing global prevalence.
• PBC predominantly affects women (10:1 ratio) and is often diagnosed via antimitochondrial antibodies, negating the need for liver biopsy in most cases.

Purpose of the Study:

• To review the current understanding of Primary Biliary Cirrhosis (PBC).
• To focus on recent advances in therapeutic strategies for PBC management.
• To highlight emerging treatments for patients with suboptimal response to ursodeoxycholic acid.

Main Methods:

• Literature review of primary biliary cirrhosis (PBC).
• Analysis of diagnostic criteria, including serological markers like antimitochondrial antibodies.
• Evaluation of treatment outcomes for ursodeoxycholic acid and assessment of emerging therapies.

Main Results:

• Ursodeoxycholic acid (UDCA) demonstrates survival benefits even in advanced PBC.
• Specific clinical and serological markers (fatigue, ANA, ACA, GP210 antibody) indicate a poorer prognosis.
• Approximately 40% of PBC patients exhibit an unsatisfactory response to UDCA, necessitating alternative treatments.

Conclusions:

• Advances in understanding PBC pathogenesis are paving the way for novel therapeutic approaches.
• New and adjunctive therapies show promise for improving outcomes in patients unresponsive to current standard-of-care.
• Future management of PBC will likely involve personalized treatment strategies incorporating these emerging therapies.